nodes	percent_of_prediction	percent_of_DWPC	metapath
Glipizide—CYP3A4—Topotecan—ovarian cancer	0.066	0.272	CbGbCtD
Glipizide—CYP2C9—Paclitaxel—ovarian cancer	0.0562	0.232	CbGbCtD
Glipizide—CYP3A4—Vinorelbine—ovarian cancer	0.0465	0.192	CbGbCtD
Glipizide—CYP3A4—Paclitaxel—ovarian cancer	0.0327	0.135	CbGbCtD
Glipizide—CYP3A4—Docetaxel—ovarian cancer	0.0236	0.0973	CbGbCtD
Glipizide—PPARG—Irinotecan—Topotecan—ovarian cancer	0.0203	1	CbGdCrCtD
Glipizide—CYP3A4—Doxorubicin—ovarian cancer	0.0176	0.0726	CbGbCtD
Glipizide—Gliclazide—VEGFA—ovarian cancer	0.00761	0.749	CrCbGaD
Glipizide—PPARG—Wnt Signaling Pathway Netpath—BCL9—ovarian cancer	0.00359	0.0359	CbGpPWpGaD
Glipizide—PPARG—Signaling events mediated by HDAC Class I—WDR77—ovarian cancer	0.00347	0.0347	CbGpPWpGaD
Glipizide—PPARG—Nuclear Receptor transcription pathway—NR5A1—ovarian cancer	0.00319	0.0318	CbGpPWpGaD
Glipizide—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—ovarian cancer	0.00219	0.0219	CbGpPWpGaD
Glipizide—ABCC8—ABC-family proteins mediated transport—ABCB1—ovarian cancer	0.00205	0.0205	CbGpPWpGaD
Glipizide—PPARG—Nuclear Receptors—PGR—ovarian cancer	0.00201	0.0201	CbGpPWpGaD
Glipizide—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—ovarian cancer	0.00199	0.0199	CbGpPWpGaD
Glipizide—KCNJ11—Type II diabetes mellitus—MTOR—ovarian cancer	0.00163	0.0163	CbGpPWpGaD
Glipizide—PPARG—Signaling events mediated by HDAC Class I—HDAC6—ovarian cancer	0.00159	0.0159	CbGpPWpGaD
Glipizide—PPARG—Nuclear Receptor transcription pathway—PGR—ovarian cancer	0.00159	0.0159	CbGpPWpGaD
Glipizide—PPARG—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.00154	0.0154	CbGpPWpGaD
Glipizide—Chlorpropamide—ABCB1—ovarian cancer	0.00152	0.15	CrCbGaD
Glipizide—ABCC8—Regulation of insulin secretion—SLC2A1—ovarian cancer	0.00141	0.0141	CbGpPWpGaD
Glipizide—PPARG—Regulation of retinoblastoma protein—SMARCA4—ovarian cancer	0.00141	0.0141	CbGpPWpGaD
Glipizide—KCNJ11—Regulation of insulin secretion—SLC2A1—ovarian cancer	0.00137	0.0137	CbGpPWpGaD
Glipizide—PPARG—Regulation of retinoblastoma protein—SKP2—ovarian cancer	0.00135	0.0135	CbGpPWpGaD
Glipizide—CYP3A4—Liver X Receptor Pathway—FASN—ovarian cancer	0.00132	0.0132	CbGpPWpGaD
Glipizide—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—ovarian cancer	0.00131	0.0131	CbGpPWpGaD
Glipizide—CYP3A4—Codeine and Morphine Metabolism—ABCB1—ovarian cancer	0.00119	0.0119	CbGpPWpGaD
Glipizide—Urticaria—Vinorelbine—ovarian cancer	0.00118	0.00191	CcSEcCtD
Glipizide—PPARG—Adipogenesis—RBL2—ovarian cancer	0.00118	0.0118	CbGpPWpGaD
Glipizide—Muscle spasms—Paclitaxel—ovarian cancer	0.00118	0.0019	CcSEcCtD
Glipizide—Abdominal pain—Vinorelbine—ovarian cancer	0.00117	0.0019	CcSEcCtD
Glipizide—ABCC8—Integration of energy metabolism—FASN—ovarian cancer	0.00117	0.0117	CbGpPWpGaD
Glipizide—Hyponatraemia—Epirubicin—ovarian cancer	0.00117	0.00189	CcSEcCtD
Glipizide—PPARG—SREBP signalling—FASN—ovarian cancer	0.00116	0.0116	CbGpPWpGaD
Glipizide—Diarrhoea—Melphalan—ovarian cancer	0.00116	0.00188	CcSEcCtD
Glipizide—Gastrointestinal haemorrhage—Epirubicin—ovarian cancer	0.00116	0.00188	CcSEcCtD
Glipizide—Diplopia—Epirubicin—ovarian cancer	0.00116	0.00188	CcSEcCtD
Glipizide—Nausea—Chlorambucil—ovarian cancer	0.00116	0.00187	CcSEcCtD
Glipizide—Vision blurred—Paclitaxel—ovarian cancer	0.00115	0.00187	CcSEcCtD
Glipizide—Visual impairment—Docetaxel—ovarian cancer	0.00115	0.00186	CcSEcCtD
Glipizide—Dizziness—Topotecan—ovarian cancer	0.00115	0.00186	CcSEcCtD
Glipizide—Tremor—Paclitaxel—ovarian cancer	0.00115	0.00186	CcSEcCtD
Glipizide—Migraine—Epirubicin—ovarian cancer	0.00114	0.00185	CcSEcCtD
Glipizide—KCNJ11—Type II diabetes mellitus—MAPK1—ovarian cancer	0.00114	0.0114	CbGpPWpGaD
Glipizide—ABCC8—Neuronal System—NSF—ovarian cancer	0.00114	0.0114	CbGpPWpGaD
Glipizide—Ill-defined disorder—Paclitaxel—ovarian cancer	0.00114	0.00184	CcSEcCtD
Glipizide—KCNJ11—Integration of energy metabolism—FASN—ovarian cancer	0.00113	0.0113	CbGpPWpGaD
Glipizide—Eye disorder—Docetaxel—ovarian cancer	0.00111	0.0018	CcSEcCtD
Glipizide—ABCC8—Integration of energy metabolism—SLC2A1—ovarian cancer	0.00111	0.0111	CbGpPWpGaD
Glipizide—KCNJ11—Neuronal System—NSF—ovarian cancer	0.00111	0.0111	CbGpPWpGaD
Glipizide—Flushing—Docetaxel—ovarian cancer	0.00111	0.00179	CcSEcCtD
Glipizide—Vomiting—Topotecan—ovarian cancer	0.0011	0.00179	CcSEcCtD
Glipizide—Malaise—Paclitaxel—ovarian cancer	0.0011	0.00179	CcSEcCtD
Glipizide—Hypoglycaemia—Doxorubicin—ovarian cancer	0.0011	0.00178	CcSEcCtD
Glipizide—Vertigo—Paclitaxel—ovarian cancer	0.0011	0.00178	CcSEcCtD
Glipizide—Syncope—Paclitaxel—ovarian cancer	0.0011	0.00178	CcSEcCtD
Glipizide—Leukopenia—Paclitaxel—ovarian cancer	0.0011	0.00177	CcSEcCtD
Glipizide—Rash—Topotecan—ovarian cancer	0.00109	0.00177	CcSEcCtD
Glipizide—Hypersensitivity—Vinorelbine—ovarian cancer	0.00109	0.00177	CcSEcCtD
Glipizide—Dermatitis—Topotecan—ovarian cancer	0.00109	0.00177	CcSEcCtD
Glipizide—Headache—Topotecan—ovarian cancer	0.00109	0.00176	CcSEcCtD
Glipizide—Vomiting—Melphalan—ovarian cancer	0.00108	0.00175	CcSEcCtD
Glipizide—Hyponatraemia—Doxorubicin—ovarian cancer	0.00108	0.00175	CcSEcCtD
Glipizide—KCNJ11—Integration of energy metabolism—SLC2A1—ovarian cancer	0.00108	0.0108	CbGpPWpGaD
Glipizide—Loss of consciousness—Paclitaxel—ovarian cancer	0.00108	0.00174	CcSEcCtD
Glipizide—Diplopia—Doxorubicin—ovarian cancer	0.00108	0.00174	CcSEcCtD
Glipizide—Gastrointestinal haemorrhage—Doxorubicin—ovarian cancer	0.00108	0.00174	CcSEcCtD
Glipizide—PPARG—Nuclear Receptors—ESR1—ovarian cancer	0.00107	0.0107	CbGpPWpGaD
Glipizide—Rash—Melphalan—ovarian cancer	0.00107	0.00173	CcSEcCtD
Glipizide—Dermatitis—Melphalan—ovarian cancer	0.00107	0.00173	CcSEcCtD
Glipizide—Chills—Docetaxel—ovarian cancer	0.00107	0.00173	CcSEcCtD
Glipizide—Asthenia—Vinorelbine—ovarian cancer	0.00107	0.00172	CcSEcCtD
Glipizide—Arrhythmia—Docetaxel—ovarian cancer	0.00106	0.00172	CcSEcCtD
Glipizide—Abdominal pain upper—Epirubicin—ovarian cancer	0.00106	0.00172	CcSEcCtD
Glipizide—Migraine—Doxorubicin—ovarian cancer	0.00106	0.00171	CcSEcCtD
Glipizide—Hypertension—Paclitaxel—ovarian cancer	0.00106	0.00171	CcSEcCtD
Glipizide—Pruritus—Vinorelbine—ovarian cancer	0.00105	0.0017	CcSEcCtD
Glipizide—Arthralgia—Paclitaxel—ovarian cancer	0.00104	0.00169	CcSEcCtD
Glipizide—Myalgia—Paclitaxel—ovarian cancer	0.00104	0.00169	CcSEcCtD
Glipizide—Anxiety—Paclitaxel—ovarian cancer	0.00104	0.00168	CcSEcCtD
Glipizide—Erythema—Docetaxel—ovarian cancer	0.00104	0.00168	CcSEcCtD
Glipizide—PPARG—Circadian rythm related genes—TOP1—ovarian cancer	0.00103	0.0103	CbGpPWpGaD
Glipizide—PPARG—Regulation of retinoblastoma protein—CCND2—ovarian cancer	0.00103	0.0103	CbGpPWpGaD
Glipizide—Nausea—Topotecan—ovarian cancer	0.00103	0.00167	CcSEcCtD
Glipizide—Discomfort—Paclitaxel—ovarian cancer	0.00103	0.00167	CcSEcCtD
Glipizide—Glyburide—ABCB1—ovarian cancer	0.00103	0.101	CrCbGaD
Glipizide—Diarrhoea—Vinorelbine—ovarian cancer	0.00102	0.00164	CcSEcCtD
Glipizide—CYP2C9—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.00101	0.0101	CbGpPWpGaD
Glipizide—Nausea—Melphalan—ovarian cancer	0.00101	0.00163	CcSEcCtD
Glipizide—Confusional state—Paclitaxel—ovarian cancer	0.00101	0.00163	CcSEcCtD
Glipizide—Oedema—Paclitaxel—ovarian cancer	0.000999	0.00162	CcSEcCtD
Glipizide—Muscle spasms—Docetaxel—ovarian cancer	0.000998	0.00161	CcSEcCtD
Glipizide—Shock—Paclitaxel—ovarian cancer	0.000983	0.00159	CcSEcCtD
Glipizide—PPARG—PPARA activates gene expression—YAP1—ovarian cancer	0.000983	0.00982	CbGpPWpGaD
Glipizide—Dizziness—Vinorelbine—ovarian cancer	0.000982	0.00159	CcSEcCtD
Glipizide—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000982	0.00159	CcSEcCtD
Glipizide—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000978	0.00158	CcSEcCtD
Glipizide—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000966	0.00156	CcSEcCtD
Glipizide—PPARG—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—YAP1—ovarian cancer	0.000962	0.00961	CbGpPWpGaD
Glipizide—Pancytopenia—Epirubicin—ovarian cancer	0.000954	0.00154	CcSEcCtD
Glipizide—Anorexia—Paclitaxel—ovarian cancer	0.000952	0.00154	CcSEcCtD
Glipizide—ABCC8—Integration of energy metabolism—PPP2R1A—ovarian cancer	0.000944	0.00943	CbGpPWpGaD
Glipizide—Vomiting—Vinorelbine—ovarian cancer	0.000944	0.00153	CcSEcCtD
Glipizide—Dysuria—Epirubicin—ovarian cancer	0.000939	0.00152	CcSEcCtD
Glipizide—Rash—Vinorelbine—ovarian cancer	0.000936	0.00152	CcSEcCtD
Glipizide—Dermatitis—Vinorelbine—ovarian cancer	0.000936	0.00151	CcSEcCtD
Glipizide—Headache—Vinorelbine—ovarian cancer	0.00093	0.00151	CcSEcCtD
Glipizide—Syncope—Docetaxel—ovarian cancer	0.00093	0.00151	CcSEcCtD
Glipizide—Leukopenia—Docetaxel—ovarian cancer	0.000929	0.0015	CcSEcCtD
Glipizide—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000917	0.00148	CcSEcCtD
Glipizide—KCNJ11—Integration of energy metabolism—PPP2R1A—ovarian cancer	0.000916	0.00915	CbGpPWpGaD
Glipizide—Loss of consciousness—Docetaxel—ovarian cancer	0.000912	0.00148	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.00091	0.00147	CcSEcCtD
Glipizide—PPARG—Circadian rythm related genes—PPP1CC—ovarian cancer	0.000905	0.00904	CbGpPWpGaD
Glipizide—PPARG—Regulation of retinoblastoma protein—CCNE1—ovarian cancer	0.000904	0.00903	CbGpPWpGaD
Glipizide—Insomnia—Paclitaxel—ovarian cancer	0.000904	0.00146	CcSEcCtD
Glipizide—Paraesthesia—Paclitaxel—ovarian cancer	0.000897	0.00145	CcSEcCtD
Glipizide—Hypertension—Docetaxel—ovarian cancer	0.000896	0.00145	CcSEcCtD
Glipizide—Drowsiness—Epirubicin—ovarian cancer	0.000896	0.00145	CcSEcCtD
Glipizide—Dyspnoea—Paclitaxel—ovarian cancer	0.000891	0.00144	CcSEcCtD
Glipizide—Somnolence—Paclitaxel—ovarian cancer	0.000888	0.00144	CcSEcCtD
Glipizide—Myalgia—Docetaxel—ovarian cancer	0.000883	0.00143	CcSEcCtD
Glipizide—Arthralgia—Docetaxel—ovarian cancer	0.000883	0.00143	CcSEcCtD
Glipizide—Pancytopenia—Doxorubicin—ovarian cancer	0.000883	0.00143	CcSEcCtD
Glipizide—Nausea—Vinorelbine—ovarian cancer	0.000882	0.00143	CcSEcCtD
Glipizide—Dyspepsia—Paclitaxel—ovarian cancer	0.000879	0.00142	CcSEcCtD
Glipizide—Jaundice—Epirubicin—ovarian cancer	0.000873	0.00141	CcSEcCtD
Glipizide—Conjunctivitis—Epirubicin—ovarian cancer	0.00087	0.00141	CcSEcCtD
Glipizide—Dysuria—Doxorubicin—ovarian cancer	0.000869	0.00141	CcSEcCtD
Glipizide—Decreased appetite—Paclitaxel—ovarian cancer	0.000868	0.00141	CcSEcCtD
Glipizide—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000862	0.0014	CcSEcCtD
Glipizide—Sweating—Epirubicin—ovarian cancer	0.000859	0.00139	CcSEcCtD
Glipizide—Pain—Paclitaxel—ovarian cancer	0.000854	0.00138	CcSEcCtD
Glipizide—Constipation—Paclitaxel—ovarian cancer	0.000854	0.00138	CcSEcCtD
Glipizide—Confusional state—Docetaxel—ovarian cancer	0.000854	0.00138	CcSEcCtD
Glipizide—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000848	0.00137	CcSEcCtD
Glipizide—PPARG—Nuclear Receptor transcription pathway—ESR1—ovarian cancer	0.000847	0.00847	CbGpPWpGaD
Glipizide—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000847	0.00137	CcSEcCtD
Glipizide—Oedema—Docetaxel—ovarian cancer	0.000847	0.00137	CcSEcCtD
Glipizide—Agranulocytosis—Epirubicin—ovarian cancer	0.000836	0.00135	CcSEcCtD
Glipizide—Shock—Docetaxel—ovarian cancer	0.000833	0.00135	CcSEcCtD
Glipizide—Thrombocytopenia—Docetaxel—ovarian cancer	0.000829	0.00134	CcSEcCtD
Glipizide—Drowsiness—Doxorubicin—ovarian cancer	0.000829	0.00134	CcSEcCtD
Glipizide—Feeling abnormal—Paclitaxel—ovarian cancer	0.000823	0.00133	CcSEcCtD
Glipizide—PPARG—embryo—ovarian cancer	0.000817	0.0929	CbGeAlD
Glipizide—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000817	0.00132	CcSEcCtD
Glipizide—Jaundice—Doxorubicin—ovarian cancer	0.000808	0.00131	CcSEcCtD
Glipizide—Anorexia—Docetaxel—ovarian cancer	0.000807	0.00131	CcSEcCtD
Glipizide—Rhinitis—Epirubicin—ovarian cancer	0.000806	0.0013	CcSEcCtD
Glipizide—Conjunctivitis—Doxorubicin—ovarian cancer	0.000805	0.0013	CcSEcCtD
Glipizide—Hepatitis—Epirubicin—ovarian cancer	0.000804	0.0013	CcSEcCtD
Glipizide—Hypoaesthesia—Epirubicin—ovarian cancer	0.0008	0.00129	CcSEcCtD
Glipizide—Pharyngitis—Epirubicin—ovarian cancer	0.000798	0.00129	CcSEcCtD
Glipizide—Sweating—Doxorubicin—ovarian cancer	0.000794	0.00129	CcSEcCtD
Glipizide—Urticaria—Paclitaxel—ovarian cancer	0.000794	0.00128	CcSEcCtD
Glipizide—Abdominal pain—Paclitaxel—ovarian cancer	0.00079	0.00128	CcSEcCtD
Glipizide—PPARG—Wnt Signaling Pathway Netpath—APC—ovarian cancer	0.000789	0.00788	CbGpPWpGaD
Glipizide—PPARG—Circadian rythm related genes—HNF1B—ovarian cancer	0.000784	0.00784	CbGpPWpGaD
Glipizide—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000784	0.00127	CcSEcCtD
Glipizide—ABCC8—endometrium—ovarian cancer	0.000783	0.0891	CbGeAlD
Glipizide—Visual impairment—Epirubicin—ovarian cancer	0.000775	0.00125	CcSEcCtD
Glipizide—Agranulocytosis—Doxorubicin—ovarian cancer	0.000773	0.00125	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000771	0.00125	CcSEcCtD
Glipizide—Insomnia—Docetaxel—ovarian cancer	0.000766	0.00124	CcSEcCtD
Glipizide—Paraesthesia—Docetaxel—ovarian cancer	0.00076	0.00123	CcSEcCtD
Glipizide—Dyspnoea—Docetaxel—ovarian cancer	0.000755	0.00122	CcSEcCtD
Glipizide—CYP3A4—Estrogen metabolism—CYP1B1—ovarian cancer	0.000754	0.00753	CbGpPWpGaD
Glipizide—Somnolence—Docetaxel—ovarian cancer	0.000753	0.00122	CcSEcCtD
Glipizide—Eye disorder—Epirubicin—ovarian cancer	0.000751	0.00122	CcSEcCtD
Glipizide—Flushing—Epirubicin—ovarian cancer	0.000746	0.00121	CcSEcCtD
Glipizide—Rhinitis—Doxorubicin—ovarian cancer	0.000746	0.00121	CcSEcCtD
Glipizide—Dyspepsia—Docetaxel—ovarian cancer	0.000745	0.00121	CcSEcCtD
Glipizide—Hepatitis—Doxorubicin—ovarian cancer	0.000744	0.0012	CcSEcCtD
Glipizide—Hypoaesthesia—Doxorubicin—ovarian cancer	0.00074	0.0012	CcSEcCtD
Glipizide—Pharyngitis—Doxorubicin—ovarian cancer	0.000738	0.00119	CcSEcCtD
Glipizide—Decreased appetite—Docetaxel—ovarian cancer	0.000736	0.00119	CcSEcCtD
Glipizide—Hypersensitivity—Paclitaxel—ovarian cancer	0.000736	0.00119	CcSEcCtD
Glipizide—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000731	0.00118	CcSEcCtD
Glipizide—Pain—Docetaxel—ovarian cancer	0.000724	0.00117	CcSEcCtD
Glipizide—Constipation—Docetaxel—ovarian cancer	0.000724	0.00117	CcSEcCtD
Glipizide—Chills—Epirubicin—ovarian cancer	0.000721	0.00117	CcSEcCtD
Glipizide—Arrhythmia—Epirubicin—ovarian cancer	0.000718	0.00116	CcSEcCtD
Glipizide—Visual impairment—Doxorubicin—ovarian cancer	0.000717	0.00116	CcSEcCtD
Glipizide—Asthenia—Paclitaxel—ovarian cancer	0.000717	0.00116	CcSEcCtD
Glipizide—Pruritus—Paclitaxel—ovarian cancer	0.000707	0.00114	CcSEcCtD
Glipizide—KCNJ11—female reproductive system—ovarian cancer	0.000705	0.0801	CbGeAlD
Glipizide—PPARG—Adipogenesis—GADD45A—ovarian cancer	0.000701	0.007	CbGpPWpGaD
Glipizide—Erythema—Epirubicin—ovarian cancer	0.0007	0.00113	CcSEcCtD
Glipizide—Feeling abnormal—Docetaxel—ovarian cancer	0.000698	0.00113	CcSEcCtD
Glipizide—Eye disorder—Doxorubicin—ovarian cancer	0.000695	0.00113	CcSEcCtD
Glipizide—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000692	0.00112	CcSEcCtD
Glipizide—PPARG—Regulation of retinoblastoma protein—MET—ovarian cancer	0.000692	0.00692	CbGpPWpGaD
Glipizide—Flushing—Doxorubicin—ovarian cancer	0.00069	0.00112	CcSEcCtD
Glipizide—Flatulence—Epirubicin—ovarian cancer	0.00069	0.00112	CcSEcCtD
Glipizide—Tension—Epirubicin—ovarian cancer	0.000687	0.00111	CcSEcCtD
Glipizide—Diarrhoea—Paclitaxel—ovarian cancer	0.000684	0.00111	CcSEcCtD
Glipizide—Nervousness—Epirubicin—ovarian cancer	0.00068	0.0011	CcSEcCtD
Glipizide—Muscle spasms—Epirubicin—ovarian cancer	0.000673	0.00109	CcSEcCtD
Glipizide—Abdominal pain—Docetaxel—ovarian cancer	0.000669	0.00108	CcSEcCtD
Glipizide—Chills—Doxorubicin—ovarian cancer	0.000667	0.00108	CcSEcCtD
Glipizide—PPARG—epithelium—ovarian cancer	0.000667	0.0758	CbGeAlD
Glipizide—CYP3A4—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000667	0.00666	CbGpPWpGaD
Glipizide—Arrhythmia—Doxorubicin—ovarian cancer	0.000665	0.00108	CcSEcCtD
Glipizide—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—YAP1—ovarian cancer	0.000663	0.00662	CbGpPWpGaD
Glipizide—Dizziness—Paclitaxel—ovarian cancer	0.000661	0.00107	CcSEcCtD
Glipizide—Vision blurred—Epirubicin—ovarian cancer	0.00066	0.00107	CcSEcCtD
Glipizide—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—ovarian cancer	0.00065	0.00649	CbGpPWpGaD
Glipizide—Ill-defined disorder—Epirubicin—ovarian cancer	0.000649	0.00105	CcSEcCtD
Glipizide—PPARG—Transcription factor regulation in adipogenesis—IL6—ovarian cancer	0.000649	0.00649	CbGpPWpGaD
Glipizide—Erythema—Doxorubicin—ovarian cancer	0.000648	0.00105	CcSEcCtD
Glipizide—KCNJ11—female gonad—ovarian cancer	0.000641	0.0729	CbGeAlD
Glipizide—Flatulence—Doxorubicin—ovarian cancer	0.000638	0.00103	CcSEcCtD
Glipizide—Tension—Doxorubicin—ovarian cancer	0.000635	0.00103	CcSEcCtD
Glipizide—Vomiting—Paclitaxel—ovarian cancer	0.000635	0.00103	CcSEcCtD
Glipizide—Malaise—Epirubicin—ovarian cancer	0.000631	0.00102	CcSEcCtD
Glipizide—PPARG—decidua—ovarian cancer	0.00063	0.0716	CbGeAlD
Glipizide—Rash—Paclitaxel—ovarian cancer	0.00063	0.00102	CcSEcCtD
Glipizide—Dermatitis—Paclitaxel—ovarian cancer	0.000629	0.00102	CcSEcCtD
Glipizide—Nervousness—Doxorubicin—ovarian cancer	0.000629	0.00102	CcSEcCtD
Glipizide—Vertigo—Epirubicin—ovarian cancer	0.000629	0.00102	CcSEcCtD
Glipizide—Syncope—Epirubicin—ovarian cancer	0.000628	0.00102	CcSEcCtD
Glipizide—Leukopenia—Epirubicin—ovarian cancer	0.000626	0.00101	CcSEcCtD
Glipizide—Headache—Paclitaxel—ovarian cancer	0.000626	0.00101	CcSEcCtD
Glipizide—Hypersensitivity—Docetaxel—ovarian cancer	0.000624	0.00101	CcSEcCtD
Glipizide—Muscle spasms—Doxorubicin—ovarian cancer	0.000623	0.00101	CcSEcCtD
Glipizide—Loss of consciousness—Epirubicin—ovarian cancer	0.000615	0.000995	CcSEcCtD
Glipizide—Vision blurred—Doxorubicin—ovarian cancer	0.00061	0.000988	CcSEcCtD
Glipizide—Asthenia—Docetaxel—ovarian cancer	0.000608	0.000983	CcSEcCtD
Glipizide—PPARG—Wnt Signaling Pathway Netpath—MTOR—ovarian cancer	0.000604	0.00604	CbGpPWpGaD
Glipizide—Hypertension—Epirubicin—ovarian cancer	0.000604	0.000978	CcSEcCtD
Glipizide—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000601	0.000972	CcSEcCtD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—ovarian cancer	0.000599	0.00599	CbGpPWpGaD
Glipizide—Pruritus—Docetaxel—ovarian cancer	0.000599	0.00097	CcSEcCtD
Glipizide—Arthralgia—Epirubicin—ovarian cancer	0.000596	0.000964	CcSEcCtD
Glipizide—Myalgia—Epirubicin—ovarian cancer	0.000596	0.000964	CcSEcCtD
Glipizide—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000594	0.00594	CbGpPWpGaD
Glipizide—Anxiety—Epirubicin—ovarian cancer	0.000594	0.000961	CcSEcCtD
Glipizide—Nausea—Paclitaxel—ovarian cancer	0.000593	0.00096	CcSEcCtD
Glipizide—Discomfort—Epirubicin—ovarian cancer	0.000589	0.000953	CcSEcCtD
Glipizide—Malaise—Doxorubicin—ovarian cancer	0.000584	0.000945	CcSEcCtD
Glipizide—Vertigo—Doxorubicin—ovarian cancer	0.000582	0.000942	CcSEcCtD
Glipizide—Syncope—Doxorubicin—ovarian cancer	0.000581	0.00094	CcSEcCtD
Glipizide—Leukopenia—Doxorubicin—ovarian cancer	0.00058	0.000938	CcSEcCtD
Glipizide—Diarrhoea—Docetaxel—ovarian cancer	0.000579	0.000938	CcSEcCtD
Glipizide—Confusional state—Epirubicin—ovarian cancer	0.000576	0.000932	CcSEcCtD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—ovarian cancer	0.000574	0.00573	CbGpPWpGaD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—ovarian cancer	0.000573	0.00572	CbGpPWpGaD
Glipizide—Oedema—Epirubicin—ovarian cancer	0.000571	0.000924	CcSEcCtD
Glipizide—Loss of consciousness—Doxorubicin—ovarian cancer	0.000569	0.000921	CcSEcCtD
Glipizide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000566	0.00566	CbGpPWpGaD
Glipizide—Shock—Epirubicin—ovarian cancer	0.000562	0.000909	CcSEcCtD
Glipizide—Dizziness—Docetaxel—ovarian cancer	0.00056	0.000906	CcSEcCtD
Glipizide—Thrombocytopenia—Epirubicin—ovarian cancer	0.000559	0.000905	CcSEcCtD
Glipizide—Hypertension—Doxorubicin—ovarian cancer	0.000559	0.000905	CcSEcCtD
Glipizide—ABCC8—Transmembrane transport of small molecules—AQP3—ovarian cancer	0.000555	0.00555	CbGpPWpGaD
Glipizide—Hyperhidrosis—Epirubicin—ovarian cancer	0.000552	0.000894	CcSEcCtD
Glipizide—Myalgia—Doxorubicin—ovarian cancer	0.000551	0.000892	CcSEcCtD
Glipizide—Arthralgia—Doxorubicin—ovarian cancer	0.000551	0.000892	CcSEcCtD
Glipizide—PPARG—uterus—ovarian cancer	0.000551	0.0627	CbGeAlD
Glipizide—PPARG—Generic Transcription Pathway—NR5A1—ovarian cancer	0.00055	0.0055	CbGpPWpGaD
Glipizide—Anxiety—Doxorubicin—ovarian cancer	0.000549	0.000889	CcSEcCtD
Glipizide—CYP3A4—Irinotecan Pathway—APC—ovarian cancer	0.000547	0.00547	CbGpPWpGaD
Glipizide—Discomfort—Doxorubicin—ovarian cancer	0.000545	0.000882	CcSEcCtD
Glipizide—Anorexia—Epirubicin—ovarian cancer	0.000544	0.000881	CcSEcCtD
Glipizide—PPARG—Wnt Signaling Pathway Netpath—CCND1—ovarian cancer	0.000541	0.00541	CbGpPWpGaD
Glipizide—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—FASN—ovarian cancer	0.00054	0.0054	CbGpPWpGaD
Glipizide—Vomiting—Docetaxel—ovarian cancer	0.000538	0.000871	CcSEcCtD
Glipizide—PPARG—Wnt Signaling Pathway Netpath—CTNNB1—ovarian cancer	0.000536	0.00535	CbGpPWpGaD
Glipizide—Rash—Docetaxel—ovarian cancer	0.000534	0.000864	CcSEcCtD
Glipizide—Dermatitis—Docetaxel—ovarian cancer	0.000533	0.000863	CcSEcCtD
Glipizide—Confusional state—Doxorubicin—ovarian cancer	0.000533	0.000862	CcSEcCtD
Glipizide—ABCC8—Transmembrane transport of small molecules—ATP7B—ovarian cancer	0.000532	0.00532	CbGpPWpGaD
Glipizide—Headache—Docetaxel—ovarian cancer	0.00053	0.000859	CcSEcCtD
Glipizide—Oedema—Doxorubicin—ovarian cancer	0.000528	0.000855	CcSEcCtD
Glipizide—ABCC8—testis—ovarian cancer	0.000524	0.0596	CbGeAlD
Glipizide—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.00052	0.000842	CcSEcCtD
Glipizide—Shock—Doxorubicin—ovarian cancer	0.00052	0.000841	CcSEcCtD
Glipizide—PPARG—Developmental Biology—NR5A1—ovarian cancer	0.000518	0.00518	CbGpPWpGaD
Glipizide—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000517	0.000837	CcSEcCtD
Glipizide—Insomnia—Epirubicin—ovarian cancer	0.000517	0.000836	CcSEcCtD
Glipizide—Paraesthesia—Epirubicin—ovarian cancer	0.000513	0.00083	CcSEcCtD
Glipizide—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000511	0.000827	CcSEcCtD
Glipizide—Dyspnoea—Epirubicin—ovarian cancer	0.000509	0.000824	CcSEcCtD
Glipizide—Somnolence—Epirubicin—ovarian cancer	0.000508	0.000822	CcSEcCtD
Glipizide—CYP2C9—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000505	0.00504	CbGpPWpGaD
Glipizide—Anorexia—Doxorubicin—ovarian cancer	0.000504	0.000815	CcSEcCtD
Glipizide—Nausea—Docetaxel—ovarian cancer	0.000503	0.000814	CcSEcCtD
Glipizide—Dyspepsia—Epirubicin—ovarian cancer	0.000503	0.000814	CcSEcCtD
Glipizide—Decreased appetite—Epirubicin—ovarian cancer	0.000496	0.000804	CcSEcCtD
Glipizide—PPARG—female reproductive system—ovarian cancer	0.000495	0.0563	CbGeAlD
Glipizide—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000493	0.000798	CcSEcCtD
Glipizide—Pain—Epirubicin—ovarian cancer	0.000488	0.00079	CcSEcCtD
Glipizide—Constipation—Epirubicin—ovarian cancer	0.000488	0.00079	CcSEcCtD
Glipizide—PPARG—SREBP signalling—MTOR—ovarian cancer	0.000482	0.00482	CbGpPWpGaD
Glipizide—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000481	0.000779	CcSEcCtD
Glipizide—ABCC8—FOXA2 and FOXA3 transcription factor networks—AKT1—ovarian cancer	0.00048	0.0048	CbGpPWpGaD
Glipizide—Insomnia—Doxorubicin—ovarian cancer	0.000478	0.000774	CcSEcCtD
Glipizide—Paraesthesia—Doxorubicin—ovarian cancer	0.000475	0.000768	CcSEcCtD
Glipizide—Dyspnoea—Doxorubicin—ovarian cancer	0.000471	0.000763	CcSEcCtD
Glipizide—Feeling abnormal—Epirubicin—ovarian cancer	0.000471	0.000762	CcSEcCtD
Glipizide—Somnolence—Doxorubicin—ovarian cancer	0.00047	0.00076	CcSEcCtD
Glipizide—PPARG—Regulation of retinoblastoma protein—CDKN1B—ovarian cancer	0.000469	0.00468	CbGpPWpGaD
Glipizide—PPARG—bone marrow—ovarian cancer	0.000468	0.0532	CbGeAlD
Glipizide—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000467	0.000756	CcSEcCtD
Glipizide—KCNJ11—FOXA2 and FOXA3 transcription factor networks—AKT1—ovarian cancer	0.000465	0.00465	CbGpPWpGaD
Glipizide—Dyspepsia—Doxorubicin—ovarian cancer	0.000465	0.000753	CcSEcCtD
Glipizide—Decreased appetite—Doxorubicin—ovarian cancer	0.000459	0.000744	CcSEcCtD
Glipizide—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000456	0.000738	CcSEcCtD
Glipizide—Urticaria—Epirubicin—ovarian cancer	0.000454	0.000734	CcSEcCtD
Glipizide—Pain—Doxorubicin—ovarian cancer	0.000452	0.000731	CcSEcCtD
Glipizide—Constipation—Doxorubicin—ovarian cancer	0.000452	0.000731	CcSEcCtD
Glipizide—Abdominal pain—Epirubicin—ovarian cancer	0.000452	0.000731	CcSEcCtD
Glipizide—PPARG—female gonad—ovarian cancer	0.000451	0.0513	CbGeAlD
Glipizide—PPARG—vagina—ovarian cancer	0.000448	0.051	CbGeAlD
Glipizide—PPARG—Regulation of retinoblastoma protein—CCND1—ovarian cancer	0.000447	0.00447	CbGpPWpGaD
Glipizide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000436	0.00436	CbGpPWpGaD
Glipizide—Feeling abnormal—Doxorubicin—ovarian cancer	0.000435	0.000705	CcSEcCtD
Glipizide—ABCC8—Metabolism—NME2—ovarian cancer	0.000434	0.00434	CbGpPWpGaD
Glipizide—PPARG—Wnt Signaling Pathway Netpath—MYC—ovarian cancer	0.000434	0.00434	CbGpPWpGaD
Glipizide—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000432	0.000699	CcSEcCtD
Glipizide—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000431	0.0043	CbGpPWpGaD
Glipizide—PPARG—Wnt Signaling Pathway Netpath—MAPK1—ovarian cancer	0.000425	0.00424	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—NME2—ovarian cancer	0.000421	0.00421	CbGpPWpGaD
Glipizide—ABCC8—Transmembrane transport of small molecules—TUBB3—ovarian cancer	0.000421	0.0042	CbGpPWpGaD
Glipizide—Hypersensitivity—Epirubicin—ovarian cancer	0.000421	0.000681	CcSEcCtD
Glipizide—Urticaria—Doxorubicin—ovarian cancer	0.00042	0.000679	CcSEcCtD
Glipizide—Abdominal pain—Doxorubicin—ovarian cancer	0.000418	0.000676	CcSEcCtD
Glipizide—KCNJ11—lymph node—ovarian cancer	0.000412	0.0469	CbGeAlD
Glipizide—Asthenia—Epirubicin—ovarian cancer	0.00041	0.000663	CcSEcCtD
Glipizide—Pruritus—Epirubicin—ovarian cancer	0.000404	0.000654	CcSEcCtD
Glipizide—PPARG—testis—ovarian cancer	0.0004	0.0455	CbGeAlD
Glipizide—PPARG—Adipogenesis—IL6ST—ovarian cancer	0.000394	0.00394	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000393	0.00393	CbGpPWpGaD
Glipizide—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000392	0.00391	CbGpPWpGaD
Glipizide—Diarrhoea—Epirubicin—ovarian cancer	0.000391	0.000632	CcSEcCtD
Glipizide—Hypersensitivity—Doxorubicin—ovarian cancer	0.000389	0.00063	CcSEcCtD
Glipizide—PPARG—Developmental Biology—HNF1B—ovarian cancer	0.000382	0.00382	CbGpPWpGaD
Glipizide—Asthenia—Doxorubicin—ovarian cancer	0.000379	0.000614	CcSEcCtD
Glipizide—Dizziness—Epirubicin—ovarian cancer	0.000378	0.000611	CcSEcCtD
Glipizide—Pruritus—Doxorubicin—ovarian cancer	0.000374	0.000605	CcSEcCtD
Glipizide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000373	0.00373	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—WDR77—ovarian cancer	0.000372	0.00372	CbGpPWpGaD
Glipizide—PPARG—Signaling events mediated by HDAC Class I—STAT3—ovarian cancer	0.000368	0.00368	CbGpPWpGaD
Glipizide—PPARG—Circadian rythm related genes—TYMS—ovarian cancer	0.000364	0.00364	CbGpPWpGaD
Glipizide—Vomiting—Epirubicin—ovarian cancer	0.000363	0.000588	CcSEcCtD
Glipizide—Diarrhoea—Doxorubicin—ovarian cancer	0.000362	0.000585	CcSEcCtD
Glipizide—Rash—Epirubicin—ovarian cancer	0.00036	0.000583	CcSEcCtD
Glipizide—Dermatitis—Epirubicin—ovarian cancer	0.00036	0.000582	CcSEcCtD
Glipizide—Headache—Epirubicin—ovarian cancer	0.000358	0.000579	CcSEcCtD
Glipizide—CYP3A4—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000356	0.00356	CbGpPWpGaD
Glipizide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000354	0.00353	CbGpPWpGaD
Glipizide—Dizziness—Doxorubicin—ovarian cancer	0.000349	0.000566	CcSEcCtD
Glipizide—Nausea—Epirubicin—ovarian cancer	0.000339	0.000549	CcSEcCtD
Glipizide—Vomiting—Doxorubicin—ovarian cancer	0.000336	0.000544	CcSEcCtD
Glipizide—Rash—Doxorubicin—ovarian cancer	0.000333	0.000539	CcSEcCtD
Glipizide—Dermatitis—Doxorubicin—ovarian cancer	0.000333	0.000539	CcSEcCtD
Glipizide—Headache—Doxorubicin—ovarian cancer	0.000331	0.000536	CcSEcCtD
Glipizide—PPARG—Generic Transcription Pathway—YAP1—ovarian cancer	0.000314	0.00314	CbGpPWpGaD
Glipizide—Nausea—Doxorubicin—ovarian cancer	0.000314	0.000508	CcSEcCtD
Glipizide—PPARG—Metabolism—NME2—ovarian cancer	0.000311	0.00311	CbGpPWpGaD
Glipizide—PPARG—Wnt Signaling Pathway Netpath—AKT1—ovarian cancer	0.000301	0.00301	CbGpPWpGaD
Glipizide—PPARG—SREBP signalling—PIK3CA—ovarian cancer	0.000294	0.00294	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—TTF1—ovarian cancer	0.000292	0.00292	CbGpPWpGaD
Glipizide—CYP2C9—female reproductive system—ovarian cancer	0.00029	0.033	CbGeAlD
Glipizide—PPARG—lymph node—ovarian cancer	0.00029	0.033	CbGeAlD
Glipizide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000288	0.00288	CbGpPWpGaD
Glipizide—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000284	0.00284	CbGpPWpGaD
Glipizide—ABCC8—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	0.000281	0.00281	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—CYTB—ovarian cancer	0.00028	0.00279	CbGpPWpGaD
Glipizide—PPARG—Generic Transcription Pathway—PGR—ovarian cancer	0.000274	0.00274	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—CYTB—ovarian cancer	0.000271	0.00271	CbGpPWpGaD
Glipizide—ABCC8—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	0.000271	0.00271	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—NR5A1—ovarian cancer	0.000265	0.00265	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000264	0.00264	CbGpPWpGaD
Glipizide—PPARG—Adipogenesis—CTNNB1—ovarian cancer	0.000257	0.00257	CbGpPWpGaD
Glipizide—PPARG—Generic Transcription Pathway—PARP1—ovarian cancer	0.000255	0.00255	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—BRIP1—ovarian cancer	0.000245	0.00244	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—PPP1CC—ovarian cancer	0.000245	0.00244	CbGpPWpGaD
Glipizide—PPARG—SREBP signalling—AKT1—ovarian cancer	0.00024	0.0024	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—PPP1CC—ovarian cancer	0.000237	0.00237	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—BRIP1—ovarian cancer	0.000237	0.00237	CbGpPWpGaD
Glipizide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000233	0.00233	CbGpPWpGaD
Glipizide—PPARG—Adipogenesis—STAT3—ovarian cancer	0.000224	0.00224	CbGpPWpGaD
Glipizide—CYP3A4—female reproductive system—ovarian cancer	0.000221	0.0252	CbGeAlD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	0.000215	0.00215	CbGpPWpGaD
Glipizide—ABCC8—Transmembrane transport of small molecules—ABCB1—ovarian cancer	0.000214	0.00214	CbGpPWpGaD
Glipizide—PPARG—Metabolism—CYTB—ovarian cancer	0.0002	0.002	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	0.000196	0.00196	CbGpPWpGaD
Glipizide—CYP2C9—Biological oxidations—CYP1B1—ovarian cancer	0.000188	0.00188	CbGpPWpGaD
Glipizide—CYP2C9—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000185	0.00185	CbGpPWpGaD
Glipizide—PPARG—Circadian rythm related genes—PTEN—ovarian cancer	0.000177	0.00177	CbGpPWpGaD
Glipizide—PPARG—Metabolism—BRIP1—ovarian cancer	0.000175	0.00175	CbGpPWpGaD
Glipizide—PPARG—Metabolism—PPP1CC—ovarian cancer	0.000175	0.00175	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—YAP1—ovarian cancer	0.000164	0.00164	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—YAP1—ovarian cancer	0.000159	0.00159	CbGpPWpGaD
Glipizide—PPARG—Adipogenesis—IL6—ovarian cancer	0.000157	0.00157	CbGpPWpGaD
Glipizide—ABCC8—Neuronal System—MAPK1—ovarian cancer	0.000155	0.00154	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—YAP1—ovarian cancer	0.000151	0.00151	CbGpPWpGaD
Glipizide—KCNJ11—Neuronal System—MAPK1—ovarian cancer	0.00015	0.0015	CbGpPWpGaD
Glipizide—PPARG—Generic Transcription Pathway—ESR1—ovarian cancer	0.000146	0.00146	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000145	0.00145	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—MET—ovarian cancer	0.000138	0.00138	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—IL6ST—ovarian cancer	0.000136	0.00135	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—FASN—ovarian cancer	0.000134	0.00134	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—PGR—ovarian cancer	0.000132	0.00132	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—SLC5A5—ovarian cancer	0.000132	0.00131	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—FASN—ovarian cancer	0.00013	0.0013	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	0.000128	0.00128	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—SLC5A5—ovarian cancer	0.000128	0.00127	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—SLC2A1—ovarian cancer	0.000127	0.00127	CbGpPWpGaD
Glipizide—ABCC8—Neuronal System—HRAS—ovarian cancer	0.000124	0.00124	CbGpPWpGaD
Glipizide—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	0.000124	0.00124	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—SLC2A1—ovarian cancer	0.000123	0.00123	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—PARP1—ovarian cancer	0.000123	0.00123	CbGpPWpGaD
Glipizide—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000122	0.00122	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—CYP1B1—ovarian cancer	0.000122	0.00122	CbGpPWpGaD
Glipizide—PPARG—Circadian rythm related genes—TP53—ovarian cancer	0.000121	0.00121	CbGpPWpGaD
Glipizide—KCNJ11—Neuronal System—HRAS—ovarian cancer	0.00012	0.0012	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—CYP1B1—ovarian cancer	0.000118	0.00118	CbGpPWpGaD
Glipizide—PPARG—Metabolism—YAP1—ovarian cancer	0.000118	0.00117	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	0.000116	0.00116	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—MMP2—ovarian cancer	0.000115	0.00115	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—NME2—ovarian cancer	0.000115	0.00114	CbGpPWpGaD
Glipizide—PPARG—Circadian rythm related genes—IL6—ovarian cancer	0.000111	0.00111	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—PPP2R1A—ovarian cancer	0.000108	0.00108	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—PPP2R1A—ovarian cancer	0.000105	0.00105	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	0.000102	0.00102	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—ERBB2—ovarian cancer	0.000101	0.00101	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—ABCB1—ovarian cancer	0.0001	0.001	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—PPP2R1A—ovarian cancer	9.95e-05	0.000994	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—TYMS—ovarian cancer	9.85e-05	0.000984	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—ABCB1—ovarian cancer	9.72e-05	0.000971	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	9.72e-05	0.000971	CbGpPWpGaD
Glipizide—PPARG—Metabolism—FASN—ovarian cancer	9.58e-05	0.000957	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—TYMS—ovarian cancer	9.55e-05	0.000954	CbGpPWpGaD
Glipizide—PPARG—Metabolism—SLC5A5—ovarian cancer	9.42e-05	0.000942	CbGpPWpGaD
Glipizide—PPARG—Metabolism—SLC2A1—ovarian cancer	9.1e-05	0.000909	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	8.91e-05	0.00089	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—CTNNB1—ovarian cancer	8.85e-05	0.000884	CbGpPWpGaD
Glipizide—PPARG—Metabolism—CYP1B1—ovarian cancer	8.73e-05	0.000872	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—MMP9—ovarian cancer	8.67e-05	0.000867	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—CAV1—ovarian cancer	7.94e-05	0.000793	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	7.92e-05	0.000792	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—VEGFA—ovarian cancer	7.79e-05	0.000778	CbGpPWpGaD
Glipizide—PPARG—Metabolism—PPP2R1A—ovarian cancer	7.74e-05	0.000773	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—STAT3—ovarian cancer	7.71e-05	0.000771	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	7.7e-05	0.000769	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—CAV1—ovarian cancer	7.69e-05	0.000769	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—NRAS—ovarian cancer	7.69e-05	0.000769	CbGpPWpGaD
Glipizide—PPARG—Generic Transcription Pathway—MYC—ovarian cancer	7.61e-05	0.000761	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—NME2—ovarian cancer	7.56e-05	0.000755	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—CYTB—ovarian cancer	7.38e-05	0.000738	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—MAPK3—ovarian cancer	7.37e-05	0.000736	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—PIK3CG—ovarian cancer	7.23e-05	0.000722	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	7.22e-05	0.000721	CbGpPWpGaD
Glipizide—PPARG—Metabolism—ABCB1—ovarian cancer	7.19e-05	0.000718	CbGpPWpGaD
Glipizide—PPARG—Metabolism—TYMS—ovarian cancer	7.06e-05	0.000705	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—ESR1—ovarian cancer	7.05e-05	0.000704	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—MAPK1—ovarian cancer	7.01e-05	0.0007	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—EGFR—ovarian cancer	7.01e-05	0.0007	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—PIK3CG—ovarian cancer	7.01e-05	0.0007	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—KRAS—ovarian cancer	6.62e-05	0.000662	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—PPP1CC—ovarian cancer	6.45e-05	0.000645	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—BRIP1—ovarian cancer	6.45e-05	0.000645	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—PIK3CD—ovarian cancer	6.35e-05	0.000635	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—PIK3CD—ovarian cancer	6.16e-05	0.000616	CbGpPWpGaD
Glipizide—PPARG—Metabolism—CAV1—ovarian cancer	5.69e-05	0.000568	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—HRAS—ovarian cancer	5.63e-05	0.000562	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—PIK3CB—ovarian cancer	5.54e-05	0.000553	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.43e-05	0.000543	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—IL6—ovarian cancer	5.39e-05	0.000538	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—PIK3CB—ovarian cancer	5.37e-05	0.000537	CbGpPWpGaD
Glipizide—PPARG—Metabolism—PIK3CG—ovarian cancer	5.18e-05	0.000518	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—AKT1—ovarian cancer	4.97e-05	0.000497	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—CYTB—ovarian cancer	4.87e-05	0.000486	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—PTEN—ovarian cancer	4.79e-05	0.000478	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	4.7e-05	0.00047	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—PTEN—ovarian cancer	4.64e-05	0.000464	CbGpPWpGaD
Glipizide—PPARG—Metabolism—PIK3CD—ovarian cancer	4.55e-05	0.000455	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—YAP1—ovarian cancer	4.33e-05	0.000432	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	4.28e-05	0.000428	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—PPP1CC—ovarian cancer	4.26e-05	0.000425	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—BRIP1—ovarian cancer	4.26e-05	0.000425	CbGpPWpGaD
Glipizide—PPARG—Metabolism—PIK3CB—ovarian cancer	3.97e-05	0.000397	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—MAPK3—ovarian cancer	3.77e-05	0.000377	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.77e-05	0.000376	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—MYC—ovarian cancer	3.67e-05	0.000366	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—FASN—ovarian cancer	3.53e-05	0.000353	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—SLC5A5—ovarian cancer	3.47e-05	0.000347	CbGpPWpGaD
Glipizide—PPARG—Metabolism—PTEN—ovarian cancer	3.43e-05	0.000343	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—PIK3CA—ovarian cancer	3.38e-05	0.000337	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—SLC2A1—ovarian cancer	3.35e-05	0.000335	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.28e-05	0.000328	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—PIK3CA—ovarian cancer	3.27e-05	0.000327	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—CYP1B1—ovarian cancer	3.21e-05	0.000321	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—YAP1—ovarian cancer	2.85e-05	0.000285	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	2.85e-05	0.000285	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.84e-05	0.000283	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—AKT1—ovarian cancer	2.76e-05	0.000276	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—AKT1—ovarian cancer	2.67e-05	0.000267	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—ABCB1—ovarian cancer	2.65e-05	0.000264	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—TYMS—ovarian cancer	2.6e-05	0.00026	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—AKT1—ovarian cancer	2.54e-05	0.000254	CbGpPWpGaD
Glipizide—PPARG—Metabolism—PIK3CA—ovarian cancer	2.42e-05	0.000242	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—FASN—ovarian cancer	2.33e-05	0.000232	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—SLC5A5—ovarian cancer	2.29e-05	0.000229	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.21e-05	0.000221	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.12e-05	0.000212	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—CAV1—ovarian cancer	2.09e-05	0.000209	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2e-05	0.0002	CbGpPWpGaD
Glipizide—PPARG—Metabolism—AKT1—ovarian cancer	1.98e-05	0.000197	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—PIK3CG—ovarian cancer	1.91e-05	0.000191	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.88e-05	0.000188	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.75e-05	0.000174	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—TYMS—ovarian cancer	1.71e-05	0.000171	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1.68e-05	0.000168	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.46e-05	0.000146	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—CAV1—ovarian cancer	1.38e-05	0.000138	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—PTEN—ovarian cancer	1.26e-05	0.000126	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.26e-05	0.000126	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.11e-05	0.00011	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—PIK3CB—ovarian cancer	9.64e-06	9.63e-05	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—PIK3CA—ovarian cancer	8.91e-06	8.9e-05	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—PTEN—ovarian cancer	8.33e-06	8.32e-05	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—AKT1—ovarian cancer	7.28e-06	7.27e-05	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—PIK3CA—ovarian cancer	5.88e-06	5.87e-05	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—AKT1—ovarian cancer	4.8e-06	4.8e-05	CbGpPWpGaD
